keyword
https://read.qxmd.com/read/25471221/hypertriglyceridemia-a-too-long-unfairly-neglected-major-cardiovascular-risk-factor
#21
REVIEW
Alexander Tenenbaum, Robert Klempfner, Enrique Z Fisman
The existence of an independent association between elevated triglyceride (TG) levels, cardiovascular (CV) risk and mortality has been largely controversial. The main difficulty in isolating the effect of hypertriglyceridemia on CV risk is the fact that elevated triglyceride levels are commonly associated with concomitant changes in high density lipoprotein (HDL), low density lipoprotein (LDL) and other lipoproteins. As a result of this problem and in disregard of the real biological role of TG, its significance as a plausible therapeutic target was unfoundedly underestimated for many years...
December 4, 2014: Cardiovascular Diabetology
https://read.qxmd.com/read/25422662/anethum-graveolens-and-hyperlipidemia-a-randomized-clinical-trial
#22
JOURNAL ARTICLE
Mahmoud Mirhosseini, Azar Baradaran, Mahmoud Rafieian-Kopaei
BACKGROUND: It has been established that hyperlipidemia increases the incidence and mortality associated with coronary heart disease. In this study, the effects of Dill (Anethum graveolens) were evaluated on lipid profile of hypercholesterolemic patients. MATERIALS AND METHODS: In this clinical study, 91 hyperlipidemic patients were randomly designated into two groups. One group received gemfibrozil (900 mg daily) and the other group received Dill tablet (six tablets daily) for 2 months...
August 2014: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://read.qxmd.com/read/25328896/vitamin-c-may-have-similar-beneficial-effects-to-gemfibrozil-on-serum-high-density-lipoprotein-cholesterol-in-type-2-diabetic-patients
#23
JOURNAL ARTICLE
Mansour Siavash, Masoud Amini
OBJECTIVE: Type 2 diabetes mellitus (DM-T2) is commonly associated with increased triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and low high-density lipoprotein cholesterol (HDL-C) levels. Fibrates like gemfibrozil are frequently used in diabetic patients to decrease TG and increase HDL-C levels. We compared the efficacy of Vitamin C, an antioxidant vitamin, with gemfibrozil on serum HDL-C in diabetic patients. METHODS: Type 2 diabetic patients, referred to our out-patient clinic were randomly divided into three groups...
July 2014: Journal of Research in Pharmacy Practice
https://read.qxmd.com/read/25183123/metabolic-effects-of-berberine-on-liver-phosphatidate-phosphohydrolase-in-rats-fed-on-high-lipogenic-diet-an-additional-mechanism-for-the-hypolipidemic-effects-of-berberine
#24
JOURNAL ARTICLE
Esfandiar Heidarian, Mahmoud Rafieian-Kopaei, Abolfazle Khoshdel, Morteza Bakhshesh
OBJECTIVE: To evaluate the effects of berberine (BBR) on the liver phosphatidate phosphohydrolase (PAP) and plasma lipids in rats fed on high lipogenic and normal diet. METHODS: Forty rats were randomly divided into 5 groups. Group I (control) received standard diet. Group II received standard diet plus 90 mg/kg BBR and Groups IV received lipogenic diet (containing sunflower oil, cholesterol and ethanol) without treatment. Groups III and V received lipogenic diet plus 90 mg/kg BBR and 30 mg/kg gemfibrozil, respectively...
May 2014: Asian Pacific Journal of Tropical Biomedicine
https://read.qxmd.com/read/24905340/ameliorative-role-of-gemfibrozil-against-partial-abdominal-aortic-constriction-induced-cardiac-hypertrophy-in-rats
#25
JOURNAL ARTICLE
Amrit Pal Singh, Randhir Singh, Pawan Krishan
Fibrates are peroxisome proliferator-activated receptor-α agonists and are clinically used for treatment of dyslipidemia and hypertriglyceridemia. Fenofibrate is reported as a cardioprotective agent in various models of cardiac dysfunction; however, limited literature is available regarding the role of gemfibrozil as a possible cardioprotective agent, especially in a non-obese model of cardiac remodelling. The present study investigated the role of gemfibrozil against partial abdominal aortic constriction-induced cardiac hypertrophy in rats...
April 2015: Cardiology in the Young
https://read.qxmd.com/read/24746832/fibrates-and-fish-oil-but-not-corn-oil-up-regulate-the-expression-of-the-cholesteryl-ester-transfer-protein-cetp-gene
#26
COMPARATIVE STUDY
Helena F Raposo, Patrícia R Patrício, Mariana C Simões, Helena C F Oliveira
Cholesteryl ester transfer protein (CETP) is a plasma protein that reduces high density lipoprotein (HDL)-cholesterol (chol) levels and may increase atherosclerosis risk. n-3 and n-6 polyunsaturated fatty acids (PUFAs) are natural ligands, and fibrates are synthetic ligands for peroxisome proliferator activated receptor-alpha (PPARα), a transcription factor that modulates lipid metabolism. In this study, we investigated the effects of PUFA oils and fibrates on CETP expression. Hypertriglyceridemic CETP transgenic mice were treated with gemfibrozil, fenofibrate, bezafibrate or vehicle (control), and normolipidemic CETP transgenic mice were treated with fenofibrate or with fish oil (FO; n-3 PUFA rich), corn oil (CO, n-6 PUFA rich) or saline...
June 2014: Journal of Nutritional Biochemistry
https://read.qxmd.com/read/24696996/hypertriglyceridemia-as-a-possible-independent-risk-factor-for-stroke
#27
REVIEW
Marijana Lisak, Vida Demarin, Zlatko Trkanjec, Vanja Basić-Kes
There are no reliable data on the relationship between ischemic stroke and elevated triglyceride levels. Results of previous studies have shown that elevated total cholesterol, high low-density lipoprotein cholesterol (LDL-C) and low high-density lipoprotein cholesterol (HDL-C) are modifiable risk factors for ischemic stroke. Recent evidence suggests that hypertriglyceridemia correlates with an increased risk of cardiovascular disease, particularly if the levels of HDL cholesterol are low and the levels of LDL cholesterol are high...
December 2013: Acta Clinica Croatica
https://read.qxmd.com/read/24327265/lipid-lowering-agents-for-nephrotic-syndrome
#28
REVIEW
Xiangyu Kong, Hao Yuan, Junming Fan, Zi Li, Taixiang Wu, Lanhui Jiang
BACKGROUND: Nephrotic syndrome is the collective name given to a group of symptoms that include proteinuria, lipiduria, hypoalbuminaemia, oedema, hypercholesterolaemia, elevated triglycerides, and hyperlipidaemia. Hyperlipidaemia is thought to aggravate glomerulosclerosis (hardening of blood vessels in the kidneys) and enhance progression of glomerular disease. Studies have established that reduction in total cholesterol and low density lipoprotein (LDL) cholesterol is associated with reduction in risk of cardiovascular diseases...
December 10, 2013: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/24160453/possible-modulation-of-fas-and-ptp-1b-signaling-in-ameliorative-potential-of-bombax-ceiba-against-high-fat-diet-induced-obesity
#29
JOURNAL ARTICLE
Paras Gupta, Rohit Goyal, Yamini Chauhan, Pyare Lal Sharma
BACKGROUND: Bombax ceiba Linn., commonly called as Semal, is used in various gastro-intestinal disturbances. It contains Lupeol which inhibits PTP-1B, adipogenesis, TG synthesis and accumulation of lipids in adipocytes and adipokines whereas the flavonoids isolated from B. ceiba has FAS inhibitory activity. The present study was aimed to investigate ameliorative potential of Bombax ceiba to experimental obesity in Wistar rats, and its possible mechanism of action. METHODS: Male Wistar albino rats weighing 180-220 g were employed in present study...
2013: BMC Complementary and Alternative Medicine
https://read.qxmd.com/read/23734746/the-efficacy-of-ezetimibe-added-to-ongoing-fibrate-statin-therapy-on-postprandial-lipid-profile-in-the-patients-with-type-2-diabetes-mellitus
#30
JOURNAL ARTICLE
Faranak Sharifi, Nima Hojeghani, Saeideh Mazloomzadeh, Zahra Shajari
BACKGROUND: Postprandial hypertriglyceridemia in diabetes mellitus can be followed by endothelial dysfunction, impaired vascular compliance and increased cardiovascular complications. So focus on better control of postprandial hypertriglyceridemia is as important as controlling fasting triglyceride level in type 2 DM. OBJECTIVE: We evaluated the effect of ezetimibe adding to fibrate or statin on postprandial hypertriglyceridemia. METHODS: In a randomized controlled clinical trial, 47 subjects with type 2 diabetes and hypertiglyceridemia were enrolled and divided in three treatment groups including Gemfibrozil 1200mg/d + placebo(group A), Ezetimibe10mg/d + Gemfibrozile 1200mg/d(group B) or Ezetimibe10mg/d + Atorvastatin10mg/d (group C) for a 6- week period...
June 4, 2013: Journal of Diabetes and Metabolic Disorders
https://read.qxmd.com/read/23677836/challenges-in-the-pharmacologic-management-of-obesity-and-secondary-dyslipidemia-in-children-and-adolescents
#31
REVIEW
Mary Jayne Kennedy, Kevin D Jellerson, Michael Z Snow, Michelle L Zacchetti
The rise in childhood obesity has lead to an increased number of children with lipid abnormalities and the predominance of a combined dyslipidemic pattern characterized by a moderate-to-severe elevation in triglycerides, normal-to-mild mild elevation in LDL cholesterol and reduced HDL cholesterol. Although recently published National Heart, Lung and Blood Institute (NHLBI) guidelines represent a significant step forward in managing primary dyslipidemias in pediatric patients, there is still no general consensus regarding the pharmacologic treatment of obesity-related lipid abnormalities in children...
October 2013: Paediatric Drugs
https://read.qxmd.com/read/23360385/temporal-changes-in-concentrations-of-lipids-and-apolipoprotein-b-among-adults-with-diagnosed-and-undiagnosed-diabetes-prediabetes-and-normoglycemia-findings-from-the-national-health-and-nutrition-examination-survey-1988-1991-to-2005-2008
#32
JOURNAL ARTICLE
Earl S Ford, Chaoyang Li, Allan Sniderman
BACKGROUND: Diabetes is characterized by profound lipid abnormalities. The objective of this study was to examine changes in concentrations of lipids and apolipoprotein B among participants stratified by glycemic status (diabetes, undiagnosed diabetes, prediabetes, and normoglycemia) in the United States from 1988-1991 to 2005-2008. METHODS: We used data from 3202 participants aged ≥20 years from the National Health and Nutrition Examination Survey (NHANES) III (1988-1991) and 3949 participants aged ≥20 years from NHANES 2005-2008...
2013: Cardiovascular Diabetology
https://read.qxmd.com/read/23100862/a-comparative-study-on-the-effects-of-gemfibrozil-diltiazem-and-isosorbide-dinitrate-on-lipid-profile-in-patients-of-ischemic-heart-disease-in-india
#33
JOURNAL ARTICLE
H O Sharma, S K Sharma
Effects of three drugs, Gemfibrozil, Diltiazem and lsosorbide dinitrate (ISDN) on various lipid parameters were studied in patients with ischemic heart disease (IHD) with positive treadmill stress response. Gemfibrozil and diltiazem significantly lowered the levels of serum total lipids (TL), triglycerides (TG), phospholipids (PL), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C), and incroased the levels of serum high density lipoprotein cholesterol (HDL-C) significantly...
December 1997: Indian Journal of Clinical Biochemistry: IJCB
https://read.qxmd.com/read/23057687/fibrates-are-an-essential-part-of-modern-anti-dyslipidemic-arsenal-spotlight-on-atherogenic-dyslipidemia-and-residual-risk-reduction
#34
REVIEW
Alexander Tenenbaum, Enrique Z Fisman
Currently the world faces epidemic of several closely related conditions: obesity, metabolic syndrome and type 2 diabetes (T2DM). The lipid profile of these patients and those with metabolic syndrome is characterized by the concurrent presence of qualitative as well as quantitative lipoprotein abnormalities: low levels of HDL, increased triglycerides, and prevalence of LDL particles that are smaller and denser than normal. This lipid phenotype has been defined as atherogenic dyslipidemia. Overwhelming evidences demonstrate that all components of the atherogenic dyslipidemia are important risk-factors for cardiovascular diseases...
2012: Cardiovascular Diabetology
https://read.qxmd.com/read/22925614/use-of-fibrates-in-clinical-practice-queensland-lipid-group-consensus-recommendations
#35
JOURNAL ARTICLE
Ian Hamilton-Craig, Karam Maximilien Kostner, Stan Woodhouse, David Colquhoun
BACKGROUND: Fibrates have been prescribed for decades as 'broad-spectrum' lipid modifying agents that can improve plasma levels of triglycerides, high-density lipoprotein cholesterol, and triglyceride-rich lipoproteins, including very low- and intermediate-density lipoproteins. Fibrates are variably effective in lowering low-density cholesterol levels. Available fibrates include gemfibrozil, fenofibrate, bezafibrate, etiofibrate and ciprofobrate; only fenofibrate and gemfibrozil are available in Australia...
September 2012: International Journal of Evidence-based Healthcare
https://read.qxmd.com/read/21966330/medicinal-chemistry-and-actions-of-dual-and-pan-ppar-modulators
#36
JOURNAL ARTICLE
Ernest Adeghate, Abdu Adem, Mohamed Y Hasan, Kornelia Tekes, Huba Kalasz
Peroxisome proliferator-activated receptor (PPAR) agonists are used as adjunct therapy in the treatment of diabetes mellitus. Fibrates, including fenofibrate, gemfibrozil, benzafibrate, ciprofibrate, and clofibrate act on PPAR alpha to reduce the level of hypertriglyceridemia. However, agonists (ligands) of PPAR-beta/delta receptors, such as tesaglitazar, muraglitazar, ragaglitazar, imiglitazar, aleglitazar, alter the body's energy substrate preference from glucose to lipids and hence contribute to the reduction of blood glucose level...
2011: Open Medicinal Chemistry Journal
https://read.qxmd.com/read/21675801/fenofibrate-a-review-of-its-lipid-modifying-effects-in-dyslipidemia-and-its-vascular-effects-in-type-2-diabetes-mellitus
#37
REVIEW
Gillian M Keating
Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α. Fenofibrate also has a number of nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein, and various pro-inflammatory markers, and improving flow-mediated dilatation) that may contribute to its clinical efficacy, particularly in terms of improving microvascular outcomes. The beneficial effects of fenofibrate on the lipid profile have been shown in a number of randomized controlled trials...
August 1, 2011: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/21358314/the-effect-of-gemfibrozil-niacin-and-cholestyramine-combination-therapy-on-metabolic-syndrome-in-the-armed-forces-regression-study
#38
RANDOMIZED CONTROLLED TRIAL
Richard A Krasuski, Ganesh P Devendra, George Cater, Edwin J Whitney
INTRODUCTION: Metabolic syndrome is a powerful predictor of cardiovascular events independent of overt diabetes. Dietary restriction and weight loss modify metabolic syndrome components. This study addresses whether combination pharmacologic therapy focused on dyslipidemia provides additional benefit. METHODS: This study examines the effect of 1 year of gemfibrozil, niacin and cholestyramine therapy on a baseline of aggressive dietary and lifestyle intervention in 143 clinically stable, nondiabetic patients with coronary disease, randomized into a double-blind, placebo-controlled trial...
May 2011: American Journal of the Medical Sciences
https://read.qxmd.com/read/21291799/flushing-and-other-dermatologic-adverse-events-associated-with-extended-release-niacin-therapy
#39
JOURNAL ARTICLE
John R Guyton, Phillip D Simmons
BACKGROUND: Niacin lowers levels of atherogenic apolipoprotein-B-containing lipoproteins, including lipoprotein(a), and raises levels of atheroprotective high-density lipoproteins. However, cutaneous flushing has been a major impediment to the clinical use of niacin. OBJECTIVE: Extended-release niacin (niacin ER) is a once-daily prescription niacin formulated to limit flushing. An analysis of flushing events with niacin ER should facilitate its clinical use. METHODS: The analysis pools previously unpublished data on flushing and related side effects from four randomized, double-blind studies of niacin ER, and also reviews long-term data on flushing from a 96-week open label, uncontrolled study...
April 2009: Journal of Clinical Lipidology
https://read.qxmd.com/read/21291775/rosuvastatin-reduces-non-high-density-lipoprotein-cholesterol-and-lipoprotein-remnants-in-patients-with-dysbetalipoproteinemia-fredrickson-type-iii-hyperlipoproteinemia
#40
JOURNAL ARTICLE
Dirk J Blom, A David Marais, Kjetil Retterstøl, Evan A Stein, Joseph Ycas, Zheng Gu, Elinor Miller
BACKGROUND: Dysbetalipoproteinemia is an uncommon genetic disorder characterized by accumulation of plasma remnant lipoproteins, severe mixed dyslipidemia, elevated apolipoprotein E levels, accelerated atherosclerosis, and premature cardiovascular disease. OBJECTIVE: To evaluate the efficacy and safety of rosuvastatin in patients with dysbetalipoproteinemia. METHODS: Following a 6-week washout, 32 patients with dysbetalipoproteinemia received rosuvastatin 10 mg, rosuvastatin 20 mg, and pravastatin 40 mg, each for 6 weeks in a randomized, double-blind, three-way crossover design...
December 2008: Journal of Clinical Lipidology
keyword
keyword
73288
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.